Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of ATLCAR.CD30.CCR4 and ATLCAR.CD30 in Relapsed/Refractory CD30+ Lymphoma
NCT03602157Phase 1Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATLCAR.CD30.CCR4 cells in Hodgkin lymphoma (HL), cutaneous T-cell lymphoma (CTCL) and grey zone lymphoma (GZL), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Adverse Events at 6 weeks. Started Oct 2018; status: active, not recruiting.
02
Drugs
ATLCAR.CD30.CCR4 cells
03
Conditions
Hodgkin lymphoma (HL)cutaneous T-cell lymphoma (CTCL)grey zone lymphoma (GZL)
Beyond the preview
Go deeper on NCT03602157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602157.